Literature DB >> 32074274

Guidance on changing therapy choice in myelofibrosis.

Donal P McLornan1, Claire N Harrison1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32074274      PMCID： PMC7042986          DOI： 10.1182/bloodadvances.2019001426

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  19 in total

1.  Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Authors:  Andrew T Kuykendall; Savan Shah; Chetasi Talati; Najla Al Ali; Kendra Sweet; Eric Padron; David A Sallman; Jeffrey E Lancet; Alan F List; Kenneth S Zuckerman; Rami S Komrokji
Journal:  Ann Hematol       Date:  2017-11-30       Impact factor: 3.673

2.  Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.

Authors:  Anne Mwirigi; Sofia Galli; Clodagh Keohane; Kavita Raj; Deepti H Radia; Claire N Harrison; Donal P McLornan
Journal:  Br J Haematol       Date:  2014-07-22       Impact factor: 6.998

3.  Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.

Authors:  Haifa Kathrin Al-Ali; Martin Griesshammer; Philipp le Coutre; Cornelius F Waller; Anna Marina Liberati; Philippe Schafhausen; Renato Tavares; Pilar Giraldo; Lynda Foltz; Pia Raanani; Vikas Gupta; Bayane Tannir; Julian Perez Ronco; Jagannath Ghosh; Bruno Martino; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-05-31       Impact factor: 9.941

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 5.  Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.

Authors:  Claire N Harrison; Donal P McLornan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Authors:  Robyn Scherber; Amylou C Dueck; Peter Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Claire N Harrison; Deepti Radia; Ruben A Mesa
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

8.  Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.

Authors:  Kate J Newberry; Keyur Patel; Lucia Masarova; Rajyalakshmi Luthra; Taghi Manshouri; Elias Jabbour; Prithviraj Bose; Naval Daver; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2017-07-03       Impact factor: 22.113

9.  Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Authors:  Ayalew Tefferi; Mythri Mudireddy; Francesco Mannelli; Kebede H Begna; Mrinal M Patnaik; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Meera Yogarajah; Valerio De Stefano; Francesco Passamonti; Vittorio Rosti; Maria Chiara Finazzi; Alessandro Rambaldi; Alberto Bosi; Paola Guglielmelli; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

10.  Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

Authors:  Srdan Verstovsek; Jason Gotlib; Ruben A Mesa; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Francisco Cervantes; Claire N Harrison; Ronald Paquette; William Sun; Ahmad Naim; Peter Langmuir; Tuochuan Dong; Prashanth Gopalakrishna; Vikas Gupta
Journal:  J Hematol Oncol       Date:  2017-09-29       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.